Follow The Filings

NBIX Neurocrine Biosciences

Neurocrine Biosciences earnings company data as of 8:01 PM ET 10/22

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 2 Nov EPS 1.99 — —
Rev — — —

Insider trades

Open-market buys and sales by NBIX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NBIX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $77.8M sold by 15 insiders under 10b5-1 plans
  1. David W. Boyer Chief Corp. Affairs Officer
    Planned sale
    $130K 826 shares at $157.45 8.7% of stake
    Traded Sep 14 Filed Sep 15
  2. Matt Abernethy CFO
    Planned sale
    $363K 2,311 shares at $157.20 5.1% of stake
    Traded Sep 14 Filed Sep 15
  3. Eric Benevich Chief Commercial Officer
    Planned sale
    $333K 2,154 shares at $154.61 3.2% of stake
    Traded Sep 9 Filed Sep 10
  4. Leslie V Norwalk Director
    Planned sale
    $228K 1,250 shares at $182.01 44% of stake
    Traded Jul 28 Filed Jul 30
  5. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $791K 4,367 shares at $181.02 21% of stake
    Traded Jul 10 Filed Jul 13
  6. Darin Lippoldt Chief Legal Officer
    Planned sale
    $1.8M 10,000 shares at $179.60 15% of stake
    Traded Jul 9 Filed Jul 13
  7. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $2.6M 14,571 shares at $178.65 47% of stake
    Traded Jul 7–9 Filed Jul 9
  8. Darin Lippoldt Chief Legal Officer
    Planned sale
    $1.7M 10,000 shares at $170.15 15% of stake
    Traded Jun 26–29 Filed Jun 30
  9. Stephen A Sherwin Director
    Planned sale
    $4.1M 25,000 shares at $165.32 61% of stake
    Traded Jun 5 Filed Jun 9
  10. Leslie V Norwalk Director
    Planned sale
    $210K 1,250 shares at $168.06 31% of stake
    Traded Jun 4 Filed Jun 8
  11. Julie Cooke Chief Human Resources Officer
    Planned sale
    $5.8M 36,937 shares at $156.22 62% of stake
    Traded Jun 2 Filed Jun 4
  12. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $354K 2,261 shares at $156.71 12% of stake
    Traded May 29 Filed Jun 2
  13. Jude Onyia Chief Scientific Officer
    Planned sale
    $1.8M 11,000 shares at $160.25 30% of stake
    Traded Jun 1 Filed Jun 2
  14. Jude Onyia Chief Scientific Officer
    Planned sale
    $1.7M 11,000 shares at $155.53 30% of stake
    Traded May 27 Filed May 29
  15. David W. Boyer Chief Corp. Affairs Officer
    Planned sale
    $609K 3,888 shares at $156.64 33% of stake
    Traded May 26 Filed May 28

Also filed in the last 12 months, not counted as buying or selling: 75 option exercises, 57 share withholdings for taxes, 20 stock grants, 6 gifts, and 1 sale to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 5.02
10-Q
8-K/A 9.01
8-K 2.02,9.01
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.